Saturday, April 19, 2014 3:32:33 PM
As I look at the $ONCS S3, it is very similar to other biotechs that are ratcheting up their pipeline. It stands to reason that IMO any new Partnerships would in exchange take $ONCS shares as well as incur additional administrative and accounting costs to file SEC/IRS details and transfer those shares to the new Partner.
Bottom line $ONCS doesn't need the S3 for ongoing details but will need the S3 for any and all details in securing the support actions for the new trials planned in 4Q2014.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM